How big is the Europe Dipeptide Peptidase 4 Inhibitors Market?

March 2024: Daiichi Sankyo made marketing alliance agreement with Mitsubishi Tanabe Pharma Corp for its DPP-4 inhibitor tablets, under the brand name Tenelia, will expire in September. The marketing deal for its SGLT2 inhibitor or Canaglu tablets will also expire that month.
July 2022: European Commission released the Commission Implementing Decision granting marketing authorization under Regulation (EC) No 726/2004 of the European Parliament and the Council for \"Sitagliptin/Metformin hydrochloride Accord - sitagliptin/metformin hydrochloride.\"

The Europe Dipeptide Peptidase 4 Inhibitors Market size is expected to reach USD 1.79 billion in 2024 and grow at a CAGR of 2.73% to reach USD 2.04 billion by 2029. Read More

What is the current Europe Dipeptide Peptidase 4 Inhibitors Market size?

In 2024, the Europe Dipeptide Peptidase 4 Inhibitors Market size is expected to reach USD 1.79 billion. Read More

Who are the key players in Europe Dipeptide Peptidase 4 Inhibitors Market?

AstraZeneca, Takeda, Novartis, Merck & Co., Inc. and Eli Lilly and Company are the major companies operating in the Europe Dipeptide Peptidase 4 Inhibitors Market. Read More

What years does this Europe Dipeptide Peptidase 4 Inhibitors Market cover, and what was the market size in 2023?

In 2023, the Europe Dipeptide Peptidase 4 Inhibitors Market size was estimated at USD 1.74 billion. The report covers the Europe Dipeptide Peptidase 4 Inhibitors Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Europe Dipeptide Peptidase 4 Inhibitors Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More